The zigzagging trajectory of the price of Daranide, now known as Keveyis, shows just how much freedom drug companies have in pricing therapies — and what a big business opportunity selling rare-disease drugs has become.
Transcription
Placed in
Where this Article is used
Loading placement connections…
Keep exploring
Related resources
More to explore from shared collections and topics.
Loading related resources…
Contribute to BackpackerU Resources
Found something worth adding?
Sign in to suggest resources and start organizing your own travel-learning library.